Literature DB >> 23845813

The state-of-the-art of approved and under-development cholera vaccines.

M Pastor1, J L Pedraz, A Esquisabel.   

Abstract

Cholera remains a huge public health problem. Although in 1894, the first cholera vaccination was reported, an ideal vaccine that meets all the requirements of the WHO has not yet been produced. Among the different approaches used for cholera vaccination, attenuated vaccines represent a major category; these vaccines are beneficial in being able to induce a strong protective response after a single administration. However, they have possible negative effects on immunocompromised patient populations. Both the licensed CVD103-HgR and other vaccine approaches under development are detailed in this article, such as the Vibrio cholerae 638 vaccine candidate, Peru-15 or CholeraGarde(®) and the VA1.3, VA1.4, IEM 108 VCUSM2 and CVD 112 vaccine candidates. In another strategy, killed V. cholerae vaccines have been developed, including Dukoral(®), mORCAX(®) and Sanchol™. The killed vaccines are already sold, and they have successfully demonstrated their potential to protect populations in endemic areas or after natural disasters. However, these vaccines do not fulfill all the requirements of the WHO because they fail to confer long-term protection, are not suitable for children under two years, require more than a single dose and require a distribution chain with cold storage. Lastly, other vaccine strategies under development are summarized in this review. Among these strategies, vaccine candidates based on alternative drug delivery systems that have been reported lately in the literature are discussed, such as microparticles, proteoliposomes, LPS subunits, DNA vaccines and rice seeds containing toxin subunits. Preliminary results reported by many groups working on alternative delivery systems for cholera vaccines demonstrate the importance of new technologies in addressing old problems such as cholera. Although a fully ideal vaccine has not yet been designed, promising steps have been reported in the literature resulting in hope for the fight against cholera.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Attenuated vaccines; Cholera vaccines; Killed vaccines

Mesh:

Substances:

Year:  2013        PMID: 23845813     DOI: 10.1016/j.vaccine.2013.06.096

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.

Authors:  Sachin N Desai; Alejandro Cravioto; Dipika Sur; Suman Kanungo
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

Review 2.  Vaccines against human diarrheal pathogens: current status and perspectives.

Authors:  Nathalie Böhles; Nathalie Böhles; Kim Busch; Kim Busch; Michael Hensel; Michael Hensel
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

Review 3.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach.

Authors:  Morteza Alizadeh; Hossein Amini-Khoei; Shahram Tahmasebian; Mahdi Ghatrehsamani; Keihan Ghatreh Samani; Yadolah Edalatpanah; Susan Rostampur; Majid Salehi; Maryam Ghasemi-Dehnoo; Fatemeh Azadegan-Dehkordi; Samira Sanami; Nader Bagheri
Journal:  Sci Rep       Date:  2022-05-11       Impact factor: 4.996

Review 5.  Critical analysis of compositions and protective efficacies of oral killed cholera vaccines.

Authors:  Shahjahan Kabir
Journal:  Clin Vaccine Immunol       Date:  2014-07-23

Review 6.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01

Review 7.  Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection.

Authors:  Jordan Poles; Yelina Alvarez; Catarina E Hioe
Journal:  AIDS Res Hum Retroviruses       Date:  2014-11       Impact factor: 2.205

Review 8.  Pandemics, pathogenicity and changing molecular epidemiology of cholera in the era of global warming.

Authors:  Fazle Rabbi Chowdhury; Zannatun Nur; Nazia Hassan; Lorenz von Seidlein; Susanna Dunachie
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-03-07       Impact factor: 3.944

Review 9.  The cholera outbreak in Yemen: lessons learned and way forward.

Authors:  Frederik Federspiel; Mohammad Ali
Journal:  BMC Public Health       Date:  2018-12-04       Impact factor: 3.295

10.  Socioeconomic drivers of vaccine uptake: An analysis of the data of a geographically defined cluster randomized cholera vaccine trial in Bangladesh.

Authors:  Amit Saha; Andrew Hayen; Mohammad Ali; Alexander Rosewell; C Raina MacIntyre; John D Clemens; Firdausi Qadri
Journal:  Vaccine       Date:  2018-05-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.